Surrozen Inc (SRZN) Peer Comparison

$24.01

$0.30 (1.27%)

As on 27-Aug-2026 16:00EDT

Market cap

$282 Mln

Revenue (TTM)

$12 Mln

P/E Ratio

--

P/B Ratio

2.5

Div. Yield

0 %

Edit

	Surrozen Inc (SRZN)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Market cap ($ Mln)	282	16,614	17,326	13,400	12,305
Revenue ($ Mln)	12	1,054	2,782	2,436	670
Net Profit ($ Mln)	-332.13	755.85	491.50	860.62	-319.95
Net Margin (%)	-2,885.33	71.69	17.67	35.33	-47.79
RoE (%)	--	--	110.09	42.98	-71.14
Price to Earnings	--	19.38	36.49	17.01	--
Price-To-Book	2.50	10.05	39.43	7.27	26.44

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Surrozen Inc (SRZN)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Operating Revenue	11.51	1,054.37	2,782.29	2,435.92	669.50
Cost of Revenue	0.11	103.47	1,982.07	85.67	19.14
Gross Profit	2.94	588.53	760.62	2,236.43	829.45
Operating Expenses	55.80	841.45	216.81	1,378.74	895.93
Operating Profit (EBIT)	-44.35	109.45	583.40	971.51	-226.44
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-332.13	101.11	598.92	1,035.47	-252.08
Provision for Tax	0.00	-654.74	107.42	174.84	20.05
Profit after Tax (Net Income)	-332.13	755.85	491.50	860.62	-319.95
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Surrozen Inc (SRZN)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Shareholder's Funds	-218.67	1,435.90	433.86	1,843.76	465.53
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Non-Current Liabilities	325.26	384.48	187.89	288.55	1,362.63
Current Liabilities	9.01	464.70	1,435.43	361.93	283.35
Total Liabilities	98.73	1,302.02	1,975.47	2,844.42	1,385.30

Assets ($ Mln)

	Surrozen Inc (SRZN)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Non-Current Assets	6.21	895.24	1,006.90	1,243.41	440.60
Current Assets	109.40	1,389.84	1,050.29	1,250.82	1,671.41
Total Assets	98.73	1,302.02	1,975.47	2,844.42	1,385.30
Total Debt*	6.32	449.89	120.10	165.93	864.07
Net Current Assets	100.39	0.00	-385.14	888.90	1,388.07

Cashflow ($ Mln)

	Surrozen Inc (SRZN)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Cash From Operating Activities	-30.24	51.77	713.22	884.27	179.55
Cash Flow from Investing Activities	-0.13	-8.15	-31.14	350.44	-129.29
Cash from Financing Activities	85.05	34.89	-860.39	-969.59	74.01
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Surrozen Inc (SRZN)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
ROCE (%)	249.47	-30.01	53.56	32.82	-0.17
ROE (%)	231.45	163.18	110.09	42.98	-71.14
ROA (%)	-285.02	26.53	15.64	29.32	-16.12
EBIT Margin (%)	-2,885.33	5.73	21.13	31.04	-0.77
Net Margin (%)	-2,885.33	71.69	17.67	35.33	-47.79
Cash Profit Margin (%)	-0.01	0.00	0.00	0.00	0.00

Growth Ratios

	Surrozen Inc (SRZN)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Revenue Growth (%)	-8.79	114.85	24.67	9.23	12.22
EBIT Growth (%)	-1,889.16	136.39	18.70	-3.99	93.17
Net Profit Growth (%)	-1,889.16	378.76	17.50	42.89	-115.58
EPS Growth (%)	-221.20	353.27	26.84	50.42	-73.87
Book Value Growth (%)	-271.26	816.12	164.02	-0.70	-13.57

Valuation Ratios

	Surrozen Inc (SRZN)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Price / Earnings	-0.85	-59.76	36.06	15.79	-2,869.63
Price / Book Value	-1.10	-80.42	35.44	5.72	10.04
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-0.51	-121.54	28.08	12.44	25.04
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Surrozen Inc (SRZN)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debt to Equity	0.00	0.00	0.00	0.00	1.77
Short term debt to equity ratio	-0.01	0.05	0.00	0.00	0.09
Current Ratio	12.14	2.99	0.73	3.46	5.90
Quick Ratio	12.14	2.32	0.73	3.38	5.90
Interest Coverage	--	1.62	--	--	-1.72

Operating Efficiency Ratios

	Surrozen Inc (SRZN)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debtors to sales (%)	43.44	21.25	15.88	13.74	1.28
Asset Turnover	0.10	0.37	0.89	0.83	0.34
Receivable days	144.39	85.52	50.42	43.48	1.50
Inventory Days	--	1,056.70	--	96.17	--
Payable days	351.65	331.01	6.26	147.97	221.81
Cash Conversion Cycle	--	811.21	--	-8.32	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly